Tag Archives: RESI

RESI Partnering Is Live: Book One-on-One Meetings For June 4th Now

10 May

By Lucy Parkinson, VP of Investor Research, LSN

On Monday June 4th, RESI will kick off Boston’s life science week with a full day of focused one-on-one partnering meetings, as well as panel and workshop content that covers the full nuances of early stage fundraising. With less than a month to go, RESI Partnering is now live, and it’s time to get your meeting requests out to these investors – and more. You can register online now

Confirmed Investors and Strategic Partners

As of May 7

At RESI, You Can Make New International Connections with Investors and Scientist Entrepreneurs

10 May

By Karen Deyo, Investor Research Analyst, LSN

Over a third of registered attendees for RESI on June 4th come from firms based outside the US. That’s an incredible audience for any early stage life science entrepreneur or investor who is looking to broaden their network and make new international connections in the global early stage life science world.

RESI’s international attendees include both startups and investors. With RESI’s afternoon track on Asia-North America Partners, LSN has seeded a venue where international connections can be made, and on June 4th RESI will be a source for both international investors and also global life science discoveries.

Life science startups from around the world have applied to the Innovation Challenge, representing countries such as Canada, France, Taiwan, and also including a large delegation from South Korea sponsored by KOTRA. Other startups attending RESI come from as far away as Australia, Argentina and Denmark.

The investors attending RESI are also from all around the world, including countries such as Malaysia, Japan and Germany. International attendees include family offices, venture capital firms, venture philanthropists and large strategic partners from across the word.
Attending RESI is a great way to meet and connect with the international life sciences community, both for companies looking to form relationships with investors and for investors looking to identify new and exciting technologies.

RESI 101: What Is RESI, What’s the Format, and Who Can You Meet There?

10 May

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

The Redefining Early Stage Investments (RESI) Conference Series is an ongoing conference series of 5 events across North America for early stage life sciences companies to source investors, create relationships, and eventually, get funding.  If you’ve never been to RESI, there’s a lot to take in.  In this article we’ll cover who you can meet at RESI, what happens throughout the day, and how RESI’s format maximizes your chance of making connections.

The RESI conference focuses on the diverse breadth of early stage investors that Life Science Nation (LSN) tracks, including Family Offices, Venture Philanthropy Funds, VCs, Angel Groups, Corporate Venture Capital Funds, and more.

The RESI Partnering Forum allows fundraising executives to identify and book up to 16 meetings with life science investors who fit their company’s technology sector and stage of development. Because RESI is a pure partnering conference the “ad hoc” meeting component is critical as the conference is arranged so that it is easy to network and investors and strategic partners have red ribbons on their badges which facilitates introductions with the scientist-entrepreneurs and fundraising CEOs who are at RESI to meet them.

Attendees, through an expansive series of panels and workshops, have the chance to hear first-hand accounts from investors explaining their current investment mandates and process for identifying and qualifying candidates.

Event format

RESI provides wrap around conference content, daylong matchmaking and networking. While the matchmaking focuses on 1 to 1 meetings and appointment setting, it is different than other similar investor events. No one is hosted. The companies that seek funding pay to attend. The investment organizations are invited to attend at no cost. As the partnering system will match the buyers and sellers together based on fit there is no guesswork as to who is selling to who which is a common problem at other events where partnering is an afterthought.

RESI Innovation Challenge: The Innovation Challenge takes place at every RESI conference and is a huge hit with early stage global investors seeking firms that align with their investment mandates. It was created for scientist-entrepreneur or fundraising CEOs starting to accumulate compelling proof-of-concept animal data or early stage clinical data. LSN has developed an expert system that facilitates the quick scoring and ranking of all of the companies and their technology assets that apply to get into the Innovation Challenge. A typical RESI conference gets over 100+ applications and LSN vets and ranks the top 30 applicants who present their technologies in an exhibition-style format throughout the full-day conference. Presenters gain additional exposure to investors and potential partners by showcasing their companies and products in a poster format. Unlike traditional 5 to 15-minute pitch presentations that do not allow any real interaction and provide no actionable feedback from investors, the RESI Innovation Challenge enables executives to pitch directly to attendees, generating more in-depth conversations with more investors.

Attendees

Funding seekers – CEOs and senior executives from life science organizations, and scientist-entrepreneurs who have invented potentially valuable technology assets.

Investors – ten categories of early stage investors and strategic channel partnerships in life science or healthcare including

  • Investment staff involved directly in an early stage life science or healthcare venture capital or private equity fund.
  • Investment staff at a family office or private wealth fund that invests in life sciences.
  • External innovation, early stage partnering or in-licensing staff from major corporations in the lifescience and healthcare industry.
  • Active life science angels or executive staff at angel organizations that invest in early stage life science companies.
  • Investment staff and executives at nonprofit organizations, venture philanthropy/impact investment firms or patient groups that provide funding to startup companies.
  • Senior management or investment staff from a pension, endowment, foundation or employee benefit plan currently invested in life sciences.

Exhibitors

  • Scientific and technical service providers looking for early stage start-ups: CROs, CMOs.
  • Business service providers: accounting, consulting, law firms.
  • Regional life science organizations: incubators, accelerators, state government, bio-clusters.

How to Use the RESI Innovation Challenge to Build Success for Your Company: An Interview with RESI Winner Steven ten Holder (Acorn Biolabs)

3 May

Steven ten Holder

An interview with Steven ten Holder, COO, Acorn Biolabs

– By Greg Mannix, VP of International Business Development, LSN

Greg Mannix

This year’s 2nd place finisher at the Innovation Challenge at RESI on MaRS was Acorn Biolabs. LSN interviewed COO, Steven ten Holder and got some key takeaways on how Acorn used the RESI Innovation Challenge effectively:

  • The Acorn team used their design and marketing skills to attract attention, rather than focusing purely on presenting scientific data
  • The team used the Innovation Challenge to create ad hoc meetings with 40 investors
  • Acorn is working to build on their success with press releases and investor follow-up after the event.

Acorn Biolabs is a Toronto-based company working out of the actual MaRS facility that has developed a novel non-invasive at-home kit to collect and viably transport cells and cryopreserve these cells as a way to ensure people will always have access to their own young therapeutically-capable cells.

Steven and Acorn’s CEO, Drew Taylor, registered quite late for RESI and didn’t have much time to set up meetings in advance. So they took more of an Ad-Hoc approach to the conference and looked to network with investors and strategics around their participation in the Innovation Challenge. It looks like it worked pretty well for them, as they placed second in the IC!

Greg Mannix: Congratulations Steven on placing second in the IC! How did you manage to get so many attendees to invest their RESI cash in Acorn Biolabs?

Steven ten Holder:  There were a couple of things that seemed to work pretty well. We put a lot of thought into our poster, keeping in mind that most of the investors passing by are probably not experts in our particular field, so we tried to keep it not too scientific, having a good balance of text and images with a nice graphic design. The goal was to be able to explain the poster to anybody who stopped by in about 2 minutes, and I think it worked.  It also helped that we had a good location, catching people as they came in.

GM: So it sounds like you spent much of the day at the actual poster. Did you get a lot of Ad-Hoc meetings there?

STH: Absolutely! I think I must have spoken to at least 30 or 40 investors at the poster. By engaging them in conversation and understanding what their interest was, I could explain our technology in more or less detail. Many of them ended up investing their RESI cash in us, so that was great!

GM:  Do you think any of those meetings will turn into a future opportunity for Acorn?

STH: Yes, I can think of 3 investors in particular who are very interested in our company and we are already following up with them.

GM: What else did you find useful about RESI?

STH:  The information on the investors in the Partnering Platform was really useful. I didn’t really have time to attend the panels, but both Drew and I did some great networking at the cocktail reception, especially after having won second prize!

GM: So what’s next?

STH: We’re definitely going to do a press release on our success at RESI.


Steven ten Holder, COO, Acorn Biolabs

– Lead Team of Bioengineers to International iGEM Competition

– Publisher Author in Novel Uses of Synthetic Biology

– Designed and Created CRISPR Viral Immunity System in Plants

Greg Mannix, VP of International Business Development, LSN

Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master’s degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in the medical devices field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg’s role at LSN is to provide international early-stage companies with the tools and strategies to succesfully fundraise and to facilitate cross-boarder investments, licensing and M&A transactions.

About Acorn Biolabs

People’s own cells have and will continue to become the foundation of the most important future biomedical therapeutics and regenerative medicine strategies. Aged cells, however, are highly mutated and deteriorated versions of our current cells. Precisely when people will need high-quality cells the most, their cells at that time will be at their worst. Acorn Biolabs has developed a novel non-invasive at-home kit to collect and viably transport cells. Acorn cryopreserves these cells as a way to ensure people will always have access to their own young therapeutically-capable cells. The value potential is immense; customer’s preserved cells are a life-long living resource, retrievable for direct use with advanced cell-based therapeutics, and analyzable for personal genomics, epigenomics, proteomics and beyond.

Insights from Genomics Investors Panelists

3 May

By Jessica Yang, Investor Research Analyst, LSN

During RESI on MaRS – as part of Toronto Health Innovation Week – we invited five panelists from renowned investment groups focusing on genomics to share their insights. How do they assess the genomics-related areas of investment?

Moderated by Ihor Boszko, Vice President, Business Development, Ontario Genomics, the Genomics Investor Panelists were:

Here are some takeaway points from the panel discussion:

Tools, platforms, and technologies
Q: What do you see as exciting opportunities on the platforms/tools side of genomics? Is it in the decentralization of sequencing? Other genomics technologies?

  1. The key is to think about what kinds of applications and markets these companies are targeting. When investors look at new sequencing platforms, they are thinking about what differentiates these new technologies from centralized sequencing – what can these platforms do that centralized sequencing cannot? For innovative genomics companies, they must identify their target markets and specific applications they want to address in the decentralized models.
  2. From different angles, all points to the same direction – the guiding principle of making investments in the healthcare arena is looking for unique and differentiated technologies that address unmet needs. The other is costs, anything expanding access while lowering the cost speaks to investor’s interests. For example, platform technologies that make things cheaper, better, or faster, making it practical in clinical settings – this is what the investors are looking for.

Direct-to-consumer in Genomics

Q: What do you think about direct-to-consumer products in Genomics?

  1. More and more direct-to-consumer products come out on the market, and it’s getting easier for everyone to do it. However, genetics and genomics are complicated. In the current healthcare system, most people aren’t trained to order or interpret the results. The challenge is that training and sophistication will lag behind the technology for computers.

Some of these direct-to-consumer tasks are negatively impacting their reputation as it relates to quality. One of the ethics dilemmas around direct-to-consumer products is that people don’t understand the terms and conditions, and some of that is companies selling consumer data,

RESI 2018 Investor Footprint

26 Apr

By Chris Cummings, Senior Marketing Manager, LSN

We are expecting significant international attendance at RESI Boston this June, due to its proximity to the BIO International Convention. Over 100 investors are already registered! The conference will be the third RESI of 2018, and is sure to continue matching early-stage investors with Biotech, Medtech, Diagnostics, and Digital Health startups. Check out some of the stats below to see what has happened so far at RESIs in 2018…


Click Here to See Investors

RESI Boston Summer: Agenda Announced

26 Apr

By Lucy Parkinson, VP of Investor Research, LSN

BIO Week 2018 starts on June 4th, and it will be a busy time for all of us in the Boston life science scene.  RESI aims to kick off the week with a full day of partnering and focused content for early stage entrepreneurs who are looking for financing and strategic relationships.  RESI Boston Summer will feature new panels on Investment Opportunities in the Microbiome, Investing In Oncology Innovation, and Investing In Mental & Behavioral Health, as well as the return of RESI’s focused discussions on Family Offices, Venture Philanthropy, Big Pharma and many other topics that span the gamut of life science investment and technology.  With an international crowd heading to Boston for the busy conference week, the Asia-North America track will provide access to advice from experienced international delegates.  We hope you can join us on June 4th.

 

%d bloggers like this: